Skip to content

Assessment of Quality of Life After Adjunct Radioiodine Therapy in Patients With Differentiated Thyroid Cancer

Effect of Radioiodine Remnant Ablation on Quality of Life in Patients With Differentiated Thyroid Cancer:a Prospective Cohort Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02706743
Enrollment
300
Registered
2016-03-11
Start date
2014-01-31
Completion date
2016-12-31
Last updated
2016-09-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid Neoplasms

Brief summary

The aim of this study was to assess the impact of adjuvant radioactive iodine therapy on the quality of life(QOL) in differentiated thyroid cancer patients and to identify independent factors affecting changes in the QOL.

Interventions

None listed

Sponsors

Southern Medical University, China
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Pathologically confirmed new diagnosis of differentiated thyroid cancer, recently treated by total thyroidectomy * Must sign a consent form before treatment * One year or more of follow-up after radioiodine ablation

Exclusion criteria

* Patients with follicular, Hürthle cell, poorly differentiated, medullary, or anaplastic thyroid carcinoma * Pregnant or lactating women * Patients that received adjuvant radioiodine treatment in the past * Patients with other cancer

Design outcomes

Primary

MeasureTime frameDescription
Change in patients with differentiated thyroid cancer from baseline Medical Outcome Study Short-Form 36(MOS SF-36) questionnaire at 12 monthsbaseline and 12 monthsThe Medical Outcome Study Short-Form 36(MOS SF-36) is a short questionnaire with 36 items which measure eight multi-item variables: physical functioning (10 items), social functioning (two items), role limitations due to physical problems(four items), role limitations due to emotional problems (three items), mental health (five items), energy and vitality (four items), pain (two items), and general perception of health (five items). For each variable item scores are coded, summed, and transformed on to a scale from 0 (worst possible health state measured by the questionnaire) to 100 (best possible health state).
Change in patients with differentiated thyroid cancer from baseline Hospital Anxiety and Depression Scale at 12 monthsbaseline and 12 monthsThe Hospital Anxiety and Depression Scale HADS is a self-rated screening questionnaire detecting mild degrees of anxiety and depression. It consists of 14 questions, seven for anxiety and seven for depression. Scores range from non-cases (0-7 score), borderline cases(8-10 score), definite cases (11-21 score).
Change in patients with differentiated thyroid cancer from baseline Brief Fatigue Inventory at 12 monthsbaseline and 12 monthsThe instrument is used to quickly assess the severity of fatigue experienced by cancer patients, as well as its impact on their ability to function over the previous 24 h.The BFI consists of 9 items on a single page. Fatigue and its interference are measured on numeric scales from 0-10. There are three items asking subjects to describe their fatigue now, at its usual level, and at its worst level during the previous 24 hours, using extreme points no fatigue and fatigue as bad as you can imagine. The next six items describe how much fatigue has interfered with aspects of their life during the previous 24 hours. Specifically, these items are general activity, mood, walking ability, normal work (both work outside the home and daily chores), relations with other people, and enjoyment of life. These interference scales range from 0 (does not interfere) to 10 (completely in terferes). The global score for the BFI is calculated as the mean value of these 9 items.

Countries

China

Contacts

Primary ContactSun Y Gang, Master
yungangsun@foxmail.com8602062783296
Backup ContactOU Y Wei, Master
oyw88@sina.com8613600474406

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026